Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne?

Br J Dermatol. 2011 Jan;164(1):182-6. doi: 10.1111/j.1365-2133.2010.10037.x. Epub 2010 Nov 23.

Abstract

Background: The main function of the human sebaceous gland is sebum excretion. Increased sebum levels combined with follicular hyperkeratinization are a prerequisite of acne vulgaris. As peroxisome proliferator-activated receptors (PPARs) are known to control lipid metabolism in several human tissues they have been considered to be involved in the pathogenesis of acne vulgaris.

Objectives: To investigate the effect of activators of PPAR-α (WY14643), PPAR-γ (rosiglitazone) and PPAR-δ (L-165.041) on basal and staurosporine-induced apoptosis in the human sebocyte cell line SZ95 in vitro.

Methods: After defining the basal effects of PPAR activators on membrane integrity (lactate dehydrogenase release) and DNA synthesis (5-bromodeoxyuridine incorporation), apoptosis was determined by the release of histone-associated DNA fragments. The underlying signalling events were detected by Western blotting and the use of specific inhibitors against p44/42 and protein kinase B (PKB)/Akt.

Results: PPAR activators of all three subsets offer antiapoptotic effects, with L-165.041 being the most potent. This compound induced the activation of PKB/Akt and p44/42, two kinases involved in antiapoptosis and proliferation, respectively. An inhibition of these kinases by specific inhibitors reversed the suppression of histone-associated DNA fragments by L-165.041, indicating that these signalling pathways participate in the observed antiapoptotic effect.

Conclusions: The present data suggest that activators of PPAR, in particular of the δ subset, might have beneficial effects on acne vulgaris by inhibiting the release of lipids in the context of sebocyte apoptosis.

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Apoptosis / drug effects*
  • Blotting, Western
  • Bromodeoxyuridine / metabolism
  • Cell Line / drug effects
  • Enzyme Inhibitors / pharmacology
  • Humans
  • L-Lactate Dehydrogenase / metabolism
  • PPAR alpha / pharmacology
  • PPAR delta / pharmacology
  • PPAR gamma / pharmacology
  • Peroxisome Proliferator-Activated Receptors / pharmacology*
  • Phenoxyacetates / pharmacology*
  • Pyrimidines / pharmacology*
  • Rosiglitazone
  • Sebaceous Glands / cytology*
  • Sebaceous Glands / drug effects
  • Staurosporine / pharmacology
  • Thiazolidinediones / pharmacology*

Substances

  • 4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid
  • Enzyme Inhibitors
  • PPAR alpha
  • PPAR delta
  • PPAR gamma
  • Peroxisome Proliferator-Activated Receptors
  • Phenoxyacetates
  • Pyrimidines
  • Thiazolidinediones
  • Rosiglitazone
  • pirinixic acid
  • L-Lactate Dehydrogenase
  • Bromodeoxyuridine
  • Staurosporine